We want to understand the recent experiences of people living in the UK who have switched from Humira to an adalimumab biosimilar medication.

If you haven't been asked to switch yet please note that we will keep this survey open for a few months so do feel that you can come back to it.	
This survey is for only for people living in the UK aged 18+	This s
1. Do you live in the UK?	1. D
O Yes O No	
 2. What area of the UK do you live in? O Scotland O Wales O Northern Ireland O Isle of Man O Channel Islands O North East and Yorkshire O North West O Midlands O East of England O South West O South East O London 	
3. Were you being treated with Humira (adalimumab) during 2018?O YesO No	(ada

4. What medical condition was your Humira primarily prescribed for? O Axial spondyloarthritis including ankylosing spondylitis (AS) O Crohn's Disease O Ulcerative colitis O Another form of IBD O Hidradenitis Suppurativa O Psoriasis O Psoriatic arthritis O Rheumatoid arthritis (RA) O Juvenile Idiopathic Arthritis (JIA) O Uveitis O Other (please specify)
5. Have you switched from Humira to an adalimumab biosimilar? O Yes O No
 6. Did your consultant, specialist nurse or pharmacist seek your consent to switch from Humira to a biosimilar? O Yes O No O Not sure / can't remember
 7. Which biosimilar medication have you switched to? ○ Amgevita ○ Hulio ○ Hyrimoz ○ Imraldi ○ Don't know/not sure

	8. How long were you taking Humira prior to being switched?						
O More the O More the	O 3 months or less O More than 3 months to 1 year O More than 1 year to 5 years O More than 5 years to 10 years O More than 10 years						
9. Thinking about the time you were being treated with Humira (adalimumab) how well do you feel your disease was controlled? Please use the scale of 1 to 5 where 1 means your condition was not controlled well at all and 5 means very well controlled							
Not at all satisfied	Somewhat dissatisfied	Neither satisfied nor dissatisfied	Somewhat satisfied	Very satisfied	N/A		
0	0	0	0	0	0		

Now, thinking about the process of switching
10. In which of the following ways did you first hear you may be asked to switch to a biosimilar?
O I was told about the potential to switch face to face in clinic by my consultant
O I was told about the potential to switch face to face in clinic by my specialist nurse
O I was invited to a patient information meeting about biosimilars
O I received a letter from the hospital
O I received a letter from the homecare delivery company
O I received a telephone call from the specialist nurse
O I received a telephone call from the homecare delivery company
O I received a telephone call from the hospital pharmacy
O I received no prior notice of my treatment being switched
O Other (please specify)

wł	. Thinking about what you heard about switching, nich of the following information did you pick up om what you were told or given in writing?
0	Switching to biosimilars will save the NHS money
0	Biosimilars are almost identical and I should notice no difference in my symptoms or side effects
0	Switching to biosimilars will mean my hospital department would benefit and might be able to offer improved services to patients
0	Switching to biosimilars means more patients would be able to get prescribed these medications
0	I had a choice and could choose not to switch if I preferred
0	I would be switched to a biosimilar medication and there were no other options
0	I was given links to more information on biosimilars (e.g. on patient organisation websites)
0	Who to contact with any queries I may have about biosimilars
0	Other (please specify)

12. Thinking about yo	our experi	ience of the	switching
process, how would y	you rate y	our satisfact	ion with

	Not at all satisfied	Somewhat dissatisfied	Neither satisfied nor dissatisfied	Somewhat satisfied	Very satisfied	N/A
The written information you received about the switch to a biosimilar	0	0	0	0	0	0
The verbal information you received about the switch from your healthcare professional	0	0	0	0	0	0
The opportunity to ask questions	0	0	0	0	0	0
The training for the new device	0	0	0	0	0	0
The ability to decline to switch	0	0	0	0	0	0
The ability to delay switching until you knew more about the biosimilar	0	0	0	0	0	0

13. What, if anything, do you think could have been done better to help the switching process run more smoothly?

Now, thir	nking abo	out the bic	similar y	ou were s	switched to	
14. How many injections of the new biosimilar would you estimate you have taken so far?						
01			07			
O 2 O 3	O 8 O 9					
0 4			0 1			
O 5 O 6			0 1	More than	10	
	f managin	•			is working for yo h Humira would	
Much worse	Slightly worse	The same	Slightly better	Much better	N/A	
0	0	0	0	0	0	
16. And v	vhat abou	t in terms o	f side effe	cts?		
Much worse	Slightly worse	The same	Slightly better	Much better	N/A	
0	0	0	0	0	0	
17. And p Much worse	ain when Slightly worse	injecting? The same	Slightly better	Much better	N/A	
0	0	0	0	0	0	
18. And the ease of using the injection device? Much Slightly The same Slightly Much N/A worse better better						
0	0	0	0	0	0	
19. And the ease of accessing the injection device via the external packaging?						
Much worse	Slightly worse	The same	Slightly better	Much better	N/A	
0	0	0	0	0	0	
20. And t	he Home	care compai	ny arrange	ments?		
Much worse	Slightly worse	The same	Slightly better	Much better	N/A	
0	0	0	0	0	0	

biosimilar?	erall, how see Scale of 1 to at all satis	to 5 whe	-	th your new y satisfied
Not at all satisfied	Somewhat satisfied	Neither	Satisfied	Very satisfied
O And why do	O you say that?	0	0	0
with your	consultant, rapist or GP	specialis	•	ou may have narmacist,
_	you feel they you solution?	iey have	they offere	ed you a
•	offered a switch offered a switch ase specify)		. •	atment

24. What do you think is most important for hospitals to be aware of as part of the switching process for new patients going forward?
25. Do you have any other comments about your experience of the biosimilar switching process?

Thank you for your time, can we just ask you for some information about yourself.

26. Gender

- O Female
- O Male
- O Other
- O Prefer not to say

27. Age

- O 18-24
- O 25-34
- O 35-44
- O 45-54
- O 55-64
- O 65+
- O Prefer not to say

If you are experiencing side effects with any medication please do remember anyone can report suspected side effects using the Yellow Card Scheme. Visit: mhra.gov.uk/yellowcard or call 0808 100 3352 for a paper form.

Do also speak to your rheumatologist or rheumatology nurse.